Despite the fact that many doctors prefer not to share their prescribing data with pharmaceutical companies, there is a sense of resignation that this data provision is a necessary evil of practicing medicine in a capitalist paradigm. However, physicians are particularly sensitive to personal information being recorded and shared among pharma sales reps.
Personal information can include conversations between the physician and the representative regarding vacation plans, recent car purchases, or children's birthdays. Information disclosed in these kinds of one-to-one interactions is generally viewed as private. Doctors are often surprised and offended by the notion that this information might be stored and shared among reps.
In the study, physicians were shown three scenarios outlining possible cumulative levels of prescribing and interaction data that pharmaceutical representatives may have available to them. These scenarios reflected industry approaches and were not based on any one client company's practice. The first scenario, depicting the most conservative level of information—including total-level monthly prescribing data, or month-to-month change in the prescribing of a rep's product—drew discomfort from the physicians. Some doctors said that even at this level, "reps have too much information available to them."
This discomfort was exacerbated when respondents were shown scenarios illustrating even more personal and specific information that could be gathered and shared amongst reps. The second scenario indicated that reps had access to total-level data for competitor products and their change month-to-month over the past year, as well as functional notes on the rep's laptop of the rep's interactions with the physician and his staff, accessible to other sales reps.
The third scenario, which elicited the greatest level of discomfort, listed dose-level monthly prescribing data for that rep's product and competitor products, detailed graphs and charts illustrating month-to-month change for all products, and personal notes on the quality of the rep/physician interaction, along with the doctor's personal details. Physicians were instructed to assume these notes—as well as prescribing data and functional/personal notes from other reps who have visited the physician—were reviewed by the rep before entering the office.
No Free Lunch
Although the sharing of personal information is not the purview of the PDRP, some physicians believe that these types of tactics will become more prevalent if the AMA were to restrict prescribing data to reps. For many, this is of equal or greater concern than rep access to their prescribing data per se.
Many physicians also presume that restricting their data will undermine the value of the relationship they have with their reps. The ability to deliver commodities, such as samples, lunches for staff, and new product information, may be hampered if reps are not equipped with prescribing data to guide their efforts.